Find out more about Kate Moodie's experience
Kate Moodie's highlights
FEATURED Journal article
Alpelisib Monotherapy for PI3K-Altered Pretreated Advanced Breast Cancer A Phase II StudyRead more
Displaying the 1 most recent project from 1 for Kate Moodie.
Displaying the 3 most recent scholarly works from 3 for Kate Moodie.
Alpelisib Monotherapy for PI3K-Altered Pretreated Advanced Breast Cancer A Phase II Study
Peter Savas, Louisa L Lo, Stephen J Luen, Elizabeth F Blackley, Jason Callahan, Kate Moodie, Courtney T van Geelen, Yi-An Ko, Chen-Fang Weng, Lironne Wein, Maria Joao Silva, Andjelija Zivanovic Bujak, Miriam M Yeung, Sarah Ftouni, Rodney J Hicks, Prudence A Francis, Chee Khoon Lee, Sarah-Jane Dawson, Sherene Loi
Journal article | 2022 | CANCER DISCOVERY
UNLABELLED: There is limited knowledge on the benefit of the α-subunit-specific PI3K inhibitor alpelisib in later lines of therapy..
Abstract P1-18-14: Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: A phase II study
Peter Savas, Louisa Lisa Lo, Stephen James Luen, Elizabeth Fay Blackley, Courtney Templeton van Geelen, Yi-An Ko, Kate Moodie, Jason William Callahan, Chen-Fang Weng, Andjelija Zivanovic Bujak, Miriam Manning Yeung, Sarah Ftouni, Prudence Anne Francis, Sarah-Jane Dawson, Sherene Loi
Conference Proceedings | 2022 | Cancer Research
Abstract Background: The PI3Kα subunit specific inhibitor alpelisib in combination with fulvestrant is approved in ..
The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations
Tamara Hettipathirana, Courtney Macdonald, Jing Xie, Kate Moodie, Chris Michael, Kelly-Anne Phillips
Journal article | 2021 | MEDICAL JOURNAL OF AUSTRALIA
OBJECTIVE: To assess the sensitivity and specificity of clinical breast examination for detecting breast cancer in asymptomatic wo..
The Sir Peter Maccallum Department of Oncology